内科理论与实践 ›› 2025, Vol. 20 ›› Issue (06): 440-448.doi: 10.16138/j.1673-6087.2025.06.03
蔡晖1a,2(
), 李幼生1b, 黄雨桦1b, 许菁菁1a, 刘庆芬1a, 顾芬3,*(
)
收稿日期:2025-01-23
出版日期:2025-12-30
发布日期:2026-01-30
通讯作者:
顾 芬 E-mail:
CAI Hui1a,2(
), LI Yousheng1b, HUANG Yuhua1b, XU Jingjing1a, LIU Qingfen1a, GU Fen3,*(
)
Received:2025-01-23
Online:2025-12-30
Published:2026-01-30
摘要:
目的:探究克罗恩病合并机会性感染的现状及其影响因素。 方法:回顾性收集2020年1月至2024年8月上海某三甲医院收治的369例克罗恩病患者的人口学特征、疾病特征、治疗方案及实验室检查结果。采用单因素分析和多因素Logistic回归分析克罗恩病合并机会性感染的影响因素。 结果:克罗恩病患者机会性感染发生率为32.25%,其中病毒感染、细菌感染及多重感染的发生率分别为16%、12.2%、3.8%。多因素Logistic回归分析显示,疾病轻度活动[优势比(odds ratio,OR) =3.22, 95% CI: 1.18~8.81, P=0.023]、疾病中度活动(OR=7.16, 95% CI: 1.88~27.31, P=0.004)、白蛋白<30 g/L(OR=4.99, 95% CI: 2.04~12.18, P<0.001)、C反应蛋白>10 mg/L(OR=3.70, 95% CI: 1.27~10.78, P=0.016)为克罗恩病合并EB病毒感染的独立危险因素。Charlson合并症指数评分为1分(OR=5.01, 95% CI: 1.51~16.60, P=0.008)、白蛋白<30 g/L(OR=3.45, 95% CI: 1.23~9.72, P=0.019)、C反应蛋白>10 mg/L(OR=13.06, 95% CI: 2.46~69.40, P=0.003)为克罗恩病合并潜伏结核分枝杆菌感染的独立危险因素。C反应蛋白>10 mg/L(OR=20.41, 95% CI: 2.13~195.52, P=0.009)为克罗恩病合并多重感染的独立危险因素。结论:疾病活动度、合并慢性病、低白蛋白血症及C反应蛋白升高为克罗恩病患者发生机会性感染的预测因素,对此类患者应进行积极预防与早期诊治。
中图分类号:
蔡晖, 李幼生, 黄雨桦, 许菁菁, 刘庆芬, 顾芬. 克罗恩病合并机会性感染的现状及影响因素分析[J]. 内科理论与实践, 2025, 20(06): 440-448.
CAI Hui, LI Yousheng, HUANG Yuhua, XU Jingjing, LIU Qingfen, GU Fen. Analysis of current status and influencing factors of opportunistic infections in Crohn disease[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(06): 440-448.
表2
CD合并机会性感染影响因素的单因素分析[n(%)/$\bar {\boldsymbol{x}} $±s/M(Q1,Q3)]
| 变量 | EBV感染 | LTBI | 其他细菌感染 | 多重感染 | |||||||||||
| 无(n=320) | 有(n=49) | P | 无(n=337) | 有(n=27) | P | 无(n=351) | 有(n=18) | P | 无(n=355) | 有(n=14) | P | ||||
| A1:确诊年龄≤16岁;A2:确诊年龄17~40岁;A3:确诊年龄>40岁。L1:回肠末端;L2:结肠;L3:回结肠;L4:上消化道。B1:非狭窄非穿透;B2:狭窄;B3:穿透;P:肛周病变。 | |||||||||||||||
| 年龄(岁) | 39.09 ± 13.25 | 39.90 ± 11.12 | 0.685 | 39.01 ± 12.84 | 41.59 ± 14.63 | 0.319 | 39.00 ± 13.01 | 43.06 ± 11.94 | 0.196 | 39.09 ± 12.97 | 41.86 ± 13.32 | 0.435 | |||
| 性别[n(%)] | 0.595 | 0.968 | 0.715 | 0.894 | |||||||||||
| 男性 | 202 (63.12) | 29 (59.18) | 214 (62.57) | 17 (62.96) | 219 (62.39) | 12 (66.67) | 222 (62.54) | 9 (64.29) | |||||||
| 女性 | 118 (36.88) | 20 (40.82) | 128 (37.43) | 10 (37.04) | 132 (37.61) | 6 (33.33) | 133 (37.46) | 5 (35.71) | |||||||
| BMI (kg/m2) | 20.13 ± 3.43 | 18.94 ± 2.64 | 0.021 | 20.01 ± 3.32 | 19.46 ± 3.80 | 0.408 | 20.07 ± 3.36 | 18.10 ± 2.71 | 0.015 | 20.03 ± 3.38 | 18.50 ± 1.96 | 0.093 | |||
| 肠内营养 [n(%)] | 0.004 | 0.984 | 0.005 | 0.222 | |||||||||||
| 无 | 127 (39.69) | 9 (18.37) | 126 (36.84) | 10 (37.04) | 135 (38.46) | 1 (5.56) | 133 (37.46) | 3 (21.43) | |||||||
| 有 | 193 (60.31) | 40 (81.63) | 216 (63.16) | 17 (62.96) | 216 (61.54) | 17 (94.44) | 222 (62.54) | 11 (78.57) | |||||||
| NRS2002评分(分) [n(%)] | 0.007 | 0.434 | 0.188 | 0.086 | |||||||||||
| 0 | 126 (39.38) | 9 (18.37) | 125 (36.55) | 10 (37.04) | 132 (37.61) | 3 (16.67) | 134 (37.75) | 1 (7.14) | |||||||
| 1 | 1 (0.31) | 0 (0.00) | 1 (0.29) | 0 (0.00) | 1 (0.28) | 0 (0.00) | 1 (0.28) | 0 (0.00) | |||||||
| 2 | 74 (23.12) | 21 (42.86) | 91 (26.61) | 4 (14.81) | 91 (25.93) | 4 (22.22) | 91 (25.63) | 4 (28.57) | |||||||
| 3 | 107 (33.44) | 16 (32.65) | 112 (32.75) | 11 (40.74) | 112 (31.91) | 11 (61.11) | 114 (32.11) | 9 (64.29) | |||||||
| 4 | 11 (3.44) | 2 (4.08) | 11 (3.22) | 2 (7.41) | 13 (3.70) | 0 (0.00) | 13 (3.66) | 0 (0.00) | |||||||
| 5 | 1 (0.31) | 1 (2.04) | 2 (0.58) | 0 (0.00) | 2 (0.57) | 0 (0.00) | 2 (0.56) | 0 (0.00) | |||||||
| 病程 (月) | 76.56 ± 70.94 | 84.31 ± 80.75 | 0.486 | 79.07 ± 73.42 | 58.85 ± 52.85 | 0.162 | 75.30 ± 70.67 | 122.17 ± 89.32 | 0.007 | 76.51 ± 71.39 | 105.07 ± 90.29 | 0.147 | |||
| CCI评分 (分)[n(%)] | 0.168 | 0.016 | 0.738 | 0.453 | |||||||||||
| 0 | 289 (90.31) | 45 (91.84) | 314 (91.81) | 20 (74.07) | 318 (90.60) | 16 (88.89) | 322 (90.70) | 12 (85.71) | |||||||
| 1 | 27 (8.44) | 2 (4.08) | 22 (6.43) | 7 (25.93) | 27 (7.69) | 2 (11.11) | 27 (7.61) | 2 (14.29) | |||||||
| 2 | 3 (0.94) | 1 (2.04) | 4 (1.17) | 0 (0.00) | 4 (1.14) | 0 (0.00) | 4 (1.13) | 0 (0.00) | |||||||
| 3 | 1 (0.31) | 1 (2.04) | 2 (0.58) | 0 (0.00) | 2 (0.57) | 0 (0.00) | 2 (0.56) | 0 (0.00) | |||||||
| 蒙特利尔分型-年龄分型[n(%)] | 0.535 | 0.022 | 0.616 | 0.173 | |||||||||||
| A1 | 18 (5.62) | 1 (2.04) | 18 (5.26) | 1 (3.70) | 18 (5.13) | 1 (5.56) | 18 (5.07) | 1 (7.14) | |||||||
| A2 | 219 (68.44) | 36 (73.47) | 242 (70.76) | 13 (48.15) | 241 (68.66) | 14 (77.78) | 248 (69.86) | 7 (50.00) | |||||||
| A3 | 83 (25.94) | 12 (24.49) | 82 (23.98) | 13 (48.15) | 92 (26.21) | 3 (16.67) | 89 (25.07) | 6 (42.86) | |||||||
| 蒙特利尔分型-疾病部位[n(%)] | 0.805 | 0.250 | 0.399 | 0.527 | |||||||||||
| L1 | 95 (29.69) | 16 (32.65) | 107 (31.29) | 4 (14.81) | 108 (30.77) | 3 (16.67) | 108 (30.42) | 3 (21.43) | |||||||
| L2 | 23 (7.19) | 3 (6.12) | 23 (6.73) | 3 (11.11) | 26 (7.41) | 0 (0.00) | 26 (7.32) | 0 (0.00) | |||||||
| L3 | 176 (55.00) | 25 (51.02) | 182 (53.22) | 19 (70.37) | 188 (53.56) | 13 (72.22) | 192 (54.08) | 9 (64.29) | |||||||
| L1+L4 | 3 (0.94) | 1 (2.04) | 4 (1.17) | 0 (0.00) | 4 (1.14) | 0 (0.00) | 4 (1.13) | 0 (0.00) | |||||||
| L3+L4 | 23 (7.19) | 4 (8.16) | 26 (7.60) | 1 (3.70) | 25 (7.12) | 2 (11.11) | 25 (7.04) | 2 (14.29) | |||||||
| 蒙特利尔分型-疾病行为[n(%)] | 0.368 | 0.389 | 0.013 | 0.009 | |||||||||||
| B1 | 62 (19.38) | 6 (12.24) | 65 (19.01) | 3 (11.11) | 68 (19.37) | 0 (0.00) | 68 (19.15) | 0 (0.00) | |||||||
| B2 | 157 (49.06) | 22 (44.90) | 161 (47.08) | 18 (66.67) | 172 (49.00) | 7 (38.89) | 173 (48.73) | 6 (42.86) | |||||||
| B3 | 48 (15.00) | 12 (24.49) | 58 (16.96) | 2 (7.41) | 57 (16.24) | 3 (16.67) | 56 (15.77) | 4 (28.57) | |||||||
| B1+P | 2 (0.62) | 0 (0.00) | 2 (0.58) | 0 (0.00) | 2 (0.57) | 0 (0.00) | 1 (0.28) | 1 (7.14) | |||||||
| B2+P | 24 (7.50) | 6 (12.24) | 29 (8.48) | 1 (3.70) | 26 (7.41) | 4 (22.22) | 30 (8.45) | 0 (0.00) | |||||||
| B3+P | 27 (8.44) | 3 (6.12) | 27 (7.89) | 3 (11.11) | 26 (7.41) | 4 (22.22) | 27 (7.61) | 3 (21.43) | |||||||
| 疾病活动度[n(%)] | <0.001 | 0.010 | 0.020 | 0.002 | |||||||||||
| 缓解期 | 270 (84.38) | 23 (46.94) | 278 (81.29) | 15 (55.56) | 283 (80.63) | 10 (55.56) | 287 (80.85) | 6 (42.86) | |||||||
| 轻度活 动期 | 36 (11.25) | 13 (26.53) | 41 (11.99) | 8 (29.63) | 45 (12.82) | 4 (22.22) | 43 (12.11) | 6 (42.86) | |||||||
| 中度活 动期 | 12 (3.75) | 11 (22.45) | 19 (5.56) | 4 (14.81) | 20 (5.70) | 3 (16.67) | 22 (6.20) | 1 (7.14) | |||||||
| 重度活 动期 | 2 (0.62) | 2 (4.08) | 4 (1.17) | 0 (0.00) | 3 (0.85) | 1 (5.56) | 3 (0.85) | 1 (7.14) | |||||||
| 5-氨基水杨酸类药物用药时长(月) | 0.00 (0.00, 15.00) | 2.00 (0.00, 36.00) | 0.257 | 0.00 (0.00, 17.00) | 7.00 (0.00, 24.00) | 0.311 | 0.00 (0.00, 17.00) | 1.00 (0.00, 57.00) | 0.298 | 0.00 (0.00, 20.00) | 0.00 (0.00, 12.50) | 0.569 | |||
| 类固醇类药物用 药时长(月) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.784 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.842 | 0.00 (0.00, 0.00) | 0.00 (0.00, 39.75) | 0.041 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.632 | |||
| 免疫抑制剂用药 时长 (月) | 18.71 ± 36.69 | 16.20 ± 37.32 | 0.657 | 18.68 ± 37.08 | 14.56 ± 32.39 | 0.575 | 18.11 ± 36.59 | 23.67 ± 40.24 | 0.532 | 18.35 ± 36.64 | 19.00 ± 40.52 | 0.948 | |||
| 生物制剂用药时长 (月) | 14.00 (4.00, 29.75) | 2.00 (0.00, 16.00) | <0.001 | 14.00 (2.00, 29.00) | 4.00 (1.00, 10.00) | 0.004 | 13.00 (2.00, 28.50) | 4.50 (1.75, 9.25) | 0.035 | 12.00 (2.00, 28.00) | 5.00 (0.00, 20.75) | 0.204 | |||
| 联合用药 [n(%)] | 0.786 | 0.092 | 0.974 | 0.525 | |||||||||||
| 无 | 293 (91.56) | 46 (93.88) | 317 (92.69) | 22 (81.48) | 323 (92.02) | 16 (88.89) | 325 (91.55) | 14 (100.00) | |||||||
| 有 | 27 (8.44) | 3 (6.12) | 25 (7.31) | 5 (18.52) | 28 (7.98) | 2 (11.11) | 30 (8.45) | 0 (0.00) | |||||||
| 白细胞计数(×109/L)[n(%)] | 0.001 | 0.127 | 0.122 | 0.259 | |||||||||||
| <4 | 49 (15.31) | 6 (12.24) | 50 (14.62) | 5 (18.52) | 53 (15.10) | 2 (11.11) | 52 (14.65) | 3 (21.43) | |||||||
| 4~10 | 241 (75.31) | 29 (59.18) | 254 (74.27) | 16 (59.26) | 259 (73.79) | 11 (61.11) | 262 (73.80) | 8 (57.14) | |||||||
| >10 | 30 (9.38) | 14 (28.57) | 38 (11.11) | 6 (22.22) | 39 (11.11) | 5 (27.78) | 41 (11.55) | 3 (21.43) | |||||||
| 中性粒细胞计数 (×109/L)[n(%)] | 0.011 | 0.110 | 0.028 | 0.072 | |||||||||||
| <2 | 28 (8.75) | 5 (10.20) | 29 (8.48) | 4 (14.81) | 31 (8.83) | 2 (11.11) | 30 (8.45) | 3 (21.43) | |||||||
| 2~7 | 256 (80.00) | 31 (63.27) | 270 (78.95) | 17 (62.96) | 277 (78.92) | 10 (55.56) | 279 (78.59) | 8 (57.14) | |||||||
| >7 | 36 (11.25) | 13 (26.53) | 43 (12.57) | 6 (22.22) | 43 (12.25) | 6 (33.33) | 46 (12.96) | 3 (21.43) | |||||||
| 淋巴细胞计数(×109/L)[n(%)] | 0.156 | 0.165 | 0.084 | 0.470 | |||||||||||
| <0.8 | 43 (13.44) | 12 (24.49) | 54 (15.79) | 1 (3.70) | 49 (13.96) | 6 (33.33) | 52 (14.65) | 3 (21.43) | |||||||
| 0.8~4.0 | 276 (86.25) | 37 (75.51) | 287 (83.92) | 26 (96.30) | 301 (85.75) | 12 (66.67) | 302 (85.07) | 11 (78.57) | |||||||
| >4.0 | 1 (0.31) | 0 (0.00) | 1 (0.29) | 0 (0.00) | 1 (0.28) | 0 (0.00) | 1 (0.28) | 0 (0.00) | |||||||
| 红细胞沉降率(mm/h)[n(%)] | 0.338 | 0.716 | 0.280 | 0.091 | |||||||||||
| ≤20 | 218 (68.12) | 30 (61.22) | 229 (66.96) | 19 (70.37) | 238 (67.81) | 10 (55.56) | 242 (68.17) | 6 (42.86) | |||||||
| >20 | 102 (31.88) | 19 (38.78) | 113 (33.04) | 8 (29.63) | 113 (32.19) | 8 (44.44) | 113 (31.83) | 8 (57.14) | |||||||
| 白蛋白(g/L)[n(%)] | < 0.001 | < 0.001 | < 0.001 | 0.011 | |||||||||||
| <30 | 41 (12.81) | 32 (65.31) | 55 (16.08) | 18 (66.67) | 63 (17.95) | 10 (55.56) | 66 (18.59) | 7 (50.00) | |||||||
| ≥30 | 279 (87.19) | 17 (34.69) | 287 (83.92) | 9 (33.33) | 288 (82.05) | 8 (44.44) | 289 (81.41) | 7 (50.00) | |||||||
| 血红蛋白(g/L)[n(%)] | 0.007 | 0.329 | < 0.001 | 0.089 | |||||||||||
| ≤110 | 106 (33.12) | 26 (53.06) | 120(35.09) | 12 (44.44) | 119 (33.90) | 13(72.22) | 124 (34.93) | 8 (57.14) | |||||||
| >110 | 214(66.88) | 23 (46.94) | 222 (64.91) | 15(55.56) | 232 (66.10) | 5 (27.78) | 231 (65.07) | 6 (42.86) | |||||||
| CRP(mg/L)[n(%)] | < 0.001 | < 0.001 | < 0.001 | < 0.001 | |||||||||||
| ≤10 | 235(73.44) | 8(16.33) | 241(70.47) | 2 (7.41) | 243 (69.23) | 0 (0.00) | 242 (68.17) | 1 (7.14) | |||||||
| >10 | 85(26.56) | 41(83.67) | 101(29.53) | 25(92.59) | 108(30.77) | 18(100.00) | 113(31.83) | 13(92.86) | |||||||
表3
CD合并EBV感染影响因素的多因素分析
| 变量 | β | SE | Z | P | OR (95%CI) |
| Inf:下确界。 | |||||
| BMI | −0.21 | 0.14 | −1.48 | 0.140 | 0.81 (0.62 ~ 1.07) |
| 肠内营养 | |||||
| 无(参照) | 1.00 | ||||
| 有 | 0.35 | 0.49 | 0.72 | 0.472 | 1.42 (0.54 ~ 3.73) |
| NRS2002评分(分) | |||||
| 0(参照) | 1.00 | ||||
| 1 | −13.01 | −0.01 | 0.993 | 0.00 (0.00 ~ inf) | |
| 2 | 0.52 | 0.68 | 0.77 | 0.444 | 1.68 (0.44 ~ 6.37) |
| 3 | −1.44 | 1.05 | −1.37 | 0.171 | 0.24 (0.03 ~ 1.86) |
| 4 | −0.95 | 1.36 | −0.70 | 0.486 | 0.39 (0.03 ~ 5.59) |
| 5 | 1.07 | 2.66 | 0.40 | 0.689 | 2.91 (0.02 ~ 537.19) |
| 疾病活动度 | |||||
| 缓解期(参照) | 1.00 | ||||
| 轻度活动期 | 1.16 | 0.51 | 2.25 | 0.025 | 3.18 (1.16 ~ 8.70) |
| 中度活动期 | 1.91 | 0.70 | 2.73 | 0.006 | 6.77 (1.71 ~ 26.81) |
| 重度活动期 | 0.07 | 1.24 | 0.06 | 0.954 | 1.07 (0.10 ~ 12.11) |
| 生物制剂用药时长 | −0.02 | 0.01 | −1.03 | 0.304 | 0.99 (0.96 ~ 1.01) |
| 白细胞计数(×109/L) | |||||
| 4~10(参照) | 1.00 | ||||
| <4 | 0.58 | 0.78 | 0.74 | 0.459 | 1.79 (0.39 ~ 8.29) |
| >10 | 1.65 | 0.97 | 1.70 | 0.090 | 5.21 (0.77 ~ 35.13) |
| 中性粒细胞计数(×109/L) | |||||
| 2~7(参照) | 1.00 | ||||
| <2 | −0.93 | 0.90 | −1.04 | 0.300 | 0.40 (0.07 ~ 2.29) |
| >7 | −0.74 | 0.97 | −0.77 | 0.442 | 0.48 (0.07 ~ 3.16) |
| 白蛋白(g/L) | |||||
| ≥30(参照) | 1.00 | ||||
| <30 | 1.60 | 0.46 | 3.50 | <.001 | 4.95 (2.02 ~ 12.10) |
| 血红蛋白(g/L) | |||||
| >110(参照) | 1.00 | ||||
| ≤110 | −0.60 | 0.48 | −1.23 | 0.219 | 0.55 (0.21 ~ 1.43) |
表4
CD合并LTBI影响因素的多因素分析
| 变量 | β | SE | Z | P | OR (95%CI) |
| Inf:下确界。 | |||||
| CRP(mg/L) | |||||
| ≤10(参照) | 1.00 | ||||
| >10 | 1.33 | 0.55 | 2.42 | 0.015 | 3.77 (1.29 ~ 11.02) |
| CCI评分(分) | |||||
| 0(参照) | 1.00 | ||||
| 1 | 1.76 | 0.62 | 2.86 | 0.004 | 5.84 (1.75 ~ 19.52) |
| 2 | −14.26 | −0.01 | 0.994 | 0.00 (0.00 ~ inf) | |
| 3 | −16.07 | -0.01 | 0.995 | 0.00 (0.00 ~inf) | |
| 疾病活动度 | |||||
| 缓解期(参照) | 1.00 | ||||
| 轻度活动期 | 0.44 | 0.55 | 0.80 | 0.425 | 1.55 (0.53 ~ 4.59) |
| 中度活动期 | -0.07 | 0.69 | −0.10 | 0.918 | 0.93 (0.24 ~ 3.60) |
| 重度活动期 | −16.52 | −0.01 | 0.993 | 0.00 (0.00 ~ inf) | |
| 生物制剂用药时长 | -0.04 | 0.02 | −1.94 | 0.052 | 0.96 (0.92 ~ 1.00) |
| 白蛋白(g/L) | |||||
| ≥30(参照) | 1.00 | ||||
| <30 | 1.18 | 0.53 | 2.22 | 0.026 | 3.27 (1.15 ~ 9.28) |
| CRP(mg/L) | |||||
| ≤10(参照) | 1.00 | ||||
| >10 | 2.50 | 0.84 | 2.97 | 0.003 | 12.15 (2.33 ~ 63.23) |
表5
CD合并多重感染影响因素的多因素分析
| 变量 | β | SE | Z | P | OR (95%CI) |
| Inf:下确界。 | |||||
| 蒙特利尔分型-疾病行为 | |||||
| B1(参照) | 1.00 | ||||
| B2 | −18.59 | 0.01 | 0.997 | 0(0.00 ~inf) | |
| B3 | −1.01 | 0.89 | 0.01 | 0.258 | 0.36(0.063 ~ 2.10) |
| B1+P | −0.35 | 0.95 | 0.01 | 0.714 | 0.71(0.11 ~ 4.52) |
| B2+P | 2.86 | 2.41 | 0 | 0.235 | 17.53 (0.16 ~ |
| B3+P | −19.27 | 0.01 | 0.998 | 0(0.00 ~ inf) | |
| 疾病活动度 | |||||
| 缓解期(参照) | 1.00 | ||||
| 轻度活动期 | 1.12 | 0.63 | 1.79 | 0.074 | 3.08 (0.90 ~ 10.53) |
| 中度活动期 | −0.40 | 1.12 | −0.36 | 0.723 | 0.67 (0.08 ~ 6.02) |
| 重度活动期 | 1.50 | 1.28 | 1.18 | 0240 | 4.49 (0.37 ~ 55.14) |
| 白蛋白(g/L) | |||||
| ≥30(参照) | 1.00 | ||||
| <30 | −0.10 | 0.62 | -0.16 | 0.871 | 0.90 (0.27 ~ 3.03) |
| CRP(mg/L) | |||||
| ≤10(参照) | 1.00 | ||||
| >10 | 3.13 | 1.12 | 2.83 | 0.005 | 22.92 (2.62 ~ 200.35) |
| [1] |
Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease[J]. Lancet, 2017, 389(10080):1741-1755.
doi: 10.1016/S0140-6736(16)31711-1 |
| [2] |
周联玉, 缪应雷. 炎症性肠病合并EB病毒感染的研究进展[J]. 中国当代医药, 2020, 27(26):24-27.
doi: 10.3969/j.issn.1674-4721.2020.26.007 |
|
Zhou LY, Miao YL. Research progression inflammatory bowel disease combined with Epstein-Barr virus infection[J]. China Modern Medicine, 2020, 27(26):24-27.
doi: 10.3969/j.issn.1674-4721.2020.26.007 |
|
| [3] |
Lee J. Cytomegalovirus infection in patients with inflammatory bowel disease[J]. Korean J Gastroenterol, 2022, 80(2):60-65.
doi: 10.4166/kjg.2022.094 |
| [4] |
Shin SH, Park SH. Viral hepatitis in patients with inflammatory bowel disease[J]. Korean J Gastroenterol, 2022, 80(2):51-59.
doi: 10.4166/kjg.2022.096 |
| [5] |
中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国克罗恩病诊治指南(2023年·广州)[J]. 胃肠病学, 2024, 29(4):200-235.
doi: 10.3760/cma.j.cn311367-20240109-00010 |
|
Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology of Chinese Medical Association, Inflammatory Bowel Disease Quality Control Center of China. Chinese clinical practice guideline on the management of Crohn′s disease (2023, Guangzhou)[J]. Chin J Gastroenterol, 2024, 29(4):200-235.
doi: 10.3760/cma.j.cn311367-20240109-00010 |
|
| [6] |
杨少武, 吴刚. 克罗恩病患者合并院内感染的危险因素分析[J]. 中华实验和临床感染病杂志(电子版), 2015, 9(3):390-392.
doi: 10.3877/cma.j.issn.1674-1358.2015.03.024 |
|
Yang SW, Wu G. Risk factors for nosocomial infections in patients with Crohn’s disease[J]. Chin J Exp Clin Infect Dis (Electronic Edition), 2015, 9(3):390-392.
doi: 10.3877/cma.j.issn.1674-1358.2015.03.024 |
|
| [7] |
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1):56-66.
doi: 10.1038/s41575-020-00360-x |
| [8] |
Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?[J]. Intest Res, 2022, 20(2):159-164.
doi: 10.5217/ir.2021.00115 |
| [9] |
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017, 390(10114):2769-2778.
doi: 10.1016/S0140-6736(17)32448-0 |
| [10] |
Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease: east meets west[J]. J Gastroenterol Hepatol, 2020, 35(3):380-389.
doi: 10.1111/jgh.14872 |
| [11] |
杨红, 金梦, 张慧敏, 等. 炎性肠病并发机会性感染及其对预后的影响[J]. 中华临床免疫和变态反应杂志, 2019, 13(2):104-107.
doi: 10.3969/j.issn.1673-8705.2019.02.003 |
|
Yang H, Jin M, Zhang HM, et al. Opportunistic infections in inflammatory bowel disease and its impact on prognosis[J]. Chin J Allergy Clin Immunol, 2019, 13(2):104-107.
doi: 10.3969/j.issn.1673-8705.2019.02.003 |
|
| [12] |
Caio G, Lungaro L, Caputo F, et al. Nutritional treatment in Crohn’s disease[J]. Nutrients, 2021, 13(5):1628.
doi: 10.3390/nu13051628 |
| [13] |
中华医学会消化病学分会炎症性肠病学组, 中华医学会肠外与肠内营养学分会胃肠病与营养协作组. 炎症性肠病营养支持治疗专家共识(第二版)[J]. 中华炎性肠病杂志(中英文), 2018, 2(3):154-172.
doi: 10.3760/cma.j.issn.0578-1426.2013.12.025 |
|
Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology of Chinese Medical Association, Gastroenterology and Nutrition Cooperative Group of Parenteral and Intestinal Nutrition Branch of Chinese Medical Association. Chinese experts consensus on nutrition support therapy in inflammatory bowel disease (the second edition)[J]. Chin J Inflamm Bowel Dis, 2018, 2(3):154-172.
doi: 10.3760/cma.j.issn.0578-1426.2013.12.025 |
|
| [14] | 严智亮, 李梦迪, 郑松柏. 克罗恩病患者营养不良特点和营养治疗进展[J]. 中华消化杂志, 2023, 43(1):65-69. |
| Yan ZL, Li MD, Zheng SB. Malnutrition features and advances in nutritional therapy for patients with Crohn’s disease[J]. Chin J Dig, 2023, 43(1):65-69. | |
| [15] | 李玥颖, 余炯言, 曾志文, 等. C反应蛋白在脓毒血症中的关键作用及研究进展[J]. 医药前沿, 2025, 15(15):28-31. |
| Li YY, Yu JY, Zeng ZW, et al. Key role and research progress of C-reactive protein in sepsis[J]. Journal of Frontiers of Medicine, 2025, 15(15):28-31. | |
| [16] |
邹俊, 王道协, 金冬花, 等. 血清IL-6、PCT、CRP联合检测诊断脓毒症的价值[J]. 临床医学, 2025, 45(5):74-76.
doi: 10.19528/j.issn.1003-3548.2025.05.023 |
|
Zou J, Wang DX, Jin DH, et al. Diagnostic value of combined detection of serum IL-6, PCT, and CRP for sepsis[J]. Clinical Medicine, 2025, 45(5):74-76.
doi: 10.19528/j.issn.1003-3548.2025.05.023 |
|
| [17] |
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection[J]. Front Immunol, 2018, 9: 754.
doi: 10.3389/fimmu.2018.00754 |
| [18] | Berbudi A, Rahmadika N, Tjahjadi AI, et al. Type 2 diabetes and its impact on the immune system[J]. Curr Diabetes Rev, 2020, 16(5):442-449. |
| [19] |
Wang W, Chen X, Pan J, et al. Epstein-Barr virus and human cytomegalovirus infection in intestinal mucosa of Chinese patients with inflammatory bowel disease[J]. Front Microbiol, 2022, 13: 915453.
doi: 10.3389/fmicb.2022.915453 |
| [20] | 周三喜. HMGCS2、PPARγ在炎症性肠病患者肠粘膜的表达与活性[D]. 2011. 广州: 南方医科大学. |
| Zhou SX. Expression and activity of HMGCS2 and PPARγ in the intestinal mucosa of patients with inflammatory bowel disease [D]. 2011. Guangzhou: Southern Medical University. | |
| [21] | Núñez Ortiz A, Rojas Feria M, de la Cruz Ramírez MD, et al. Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes[J]. Rev Esp Enferm Dig, 2022, 114(5):259-265. |
| [22] | Beaugerie L, Rahier JF, Kirchgesner J. Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases [J]. Clin Gastroenterol Hepatol, 2020, 18(6):1324-1335. |
| [1] | 王敏慧, 康磊. 重症监护病房患者的尊严现状及影响因素分析[J]. 内科理论与实践, 2026, 21(01): 46-52. |
| [2] | 陈丽娟, 罗灿伟, 刘琳珊, 李佳佳, 黄少兰, 李凌华, 刘聪. 育龄期女性人类免疫缺陷病毒感染者乐观水平现状及影响因素分析[J]. 内科理论与实践, 2026, 21(01): 39-45. |
| [3] | 王延丽, 侯明杰, 原海珍, 辛宁波, 张玉伟, 韩磊, 张一帆, 马玉青, 赵清霞. 322例河南省人类免疫缺陷病毒感染/获得性免疫缺陷综合征合并肺部感染患者的病原学特征分析[J]. 内科理论与实践, 2026, 21(01): 21-27. |
| [4] | . 基于多种影响因素的电动汽车充电负荷建模方法[J]. J Shanghai Jiaotong Univ Sci, 2025, 30(6): 1232-1241. |
| [5] | 唐雨杭, 喻锟, 曾祥君, 倪砚茹, 程新翔, 韩炜. 基于地电位分布的地铁杂散电流引起埋地金属腐蚀计算方法[J]. 上海交通大学学报, 2025, 59(3): 424-434. |
| [6] | 刘贤权1, 姜伟2. 深水钻井隔水导管纵向振动特性研究及其应用[J]. 海洋工程装备与技术, 2025, 12(1): 100-105. |
| [7] | 刘新义, 周燕春, 张昳丽, 等.
先天性小耳畸形患者焦虑抑郁现状及影响因素分析
[J]. 组织工程与重建外科杂志, 2025, 21(1): 68-. |
| [8] | 王甜, 杨敏利. 唇腭裂术前呼吸道感染及手术预后相关影响因素与预测模型构建[J]. 组织工程与重建外科杂志, 2025, 21(1): 40-. |
| [9] | 张平新, 杨洁, 王杨迪, 陈旻湖, 李雪华, 毛仁. 克罗恩病肠道纤维化的无创定量诊断研究进展[J]. 诊断学理论与实践, 2025, 24(04): 383-392. |
| [10] | 杨翠萍, 陈平. 全球炎症性肠病的流行趋势分析及诊治现状[J]. 诊断学理论与实践, 2025, 24(04): 373-382. |
| [11] | 孙欣, 王思敏, 谢敬东, 江海林, 王森. 考虑多维影响因素的改进Transformer-PSO短期电价预测方法[J]. 上海交通大学学报, 2024, 58(9): 1420-1431. |
| [12] | 江燕, 冉雪会, 林晓曦, 等. 头颈部葡萄酒色斑患者的病耻感现状及其影响因素 [J]. 组织工程与重建外科杂志, 2024, 20(3): 335-. |
| [13] | 郝子佳, 邢倩, 胡丹丹, 等. 增生性瘢痕的影响因素分析及风险预测模型研究 [J]. 组织工程与重建外科杂志, 2024, 20(2): 190-. |
| [14] | 程健珊, 张弢, 吴珺玮, 高惠峰, 陈敬贤, 孟志强. 华蟾素片联合肝动脉化疗栓塞术治疗原发性肝细胞癌的临床疗效及其影响因素分析[J]. 外科理论与实践, 2024, 29(04): 351-357. |
| [15] | 龚婷婷, 钱爱华, 陈希. 个体化预测早期胃癌内镜黏膜下剥离术后迟发性出血风险的列线图模型构建[J]. 外科理论与实践, 2024, 29(03): 236-242. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||